Immunotech Biopharm Ltd (HK:6978)
:6978
Want to see HK:6978 full AI Analyst Report?
Total Valuation
Immunotech Biopharm Ltd has a market cap or net worth of HK$351.98M. The enterprise value is HK$642.51M.
Market CapHK$351.98M
Enterprise ValueHK$642.51M
Share Statistics
Immunotech Biopharm Ltd has 617,500,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding617,500,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immunotech Biopharm Ltd’s return on equity (ROE) is 16.56 and return on invested capital (ROIC) is -32.83%.
Return on Equity (ROE)16.56
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-32.83%
Return on Capital Employed (ROCE)-1.39
Revenue Per Employee0.00
Profits Per Employee-1.50M
Employee Count154
Asset Turnover0.00
Inventory Turnover11.92
Valuation Ratios
The current PE Ratio of Immunotech Biopharm Ltd is ―. Immunotech Biopharm Ltd’s PEG ratio is -0.38.
PE Ratio―
PS Ratio0.00
PB Ratio-103.70
Price to Fair Value-103.70
Price to FCF-12.91
Price to Operating Cash Flow-2.80
PEG Ratio-0.38
Income Statement
In the last 12 months, Immunotech Biopharm Ltd had revenue of 0.00 and earned -230.78M in profits. Earnings per share was -0.42.
Revenue0.00
Gross Profit-53.87M
Operating Income-155.80M
Pretax Income-230.91M
Net Income-230.78M
EBITDA-115.49M
Earnings Per Share (EPS)-0.42
Cash Flow
In the last 12 months, operating cash flow was -107.09M and capital expenditures -14.80M, giving a free cash flow of -121.89M billion.
Operating Cash Flow-107.09M
Free Cash Flow-121.89M
Free Cash Flow per Share-0.20
Dividends & Yields
Immunotech Biopharm Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-79.06%
50-Day Moving Average1.59
200-Day Moving Average2.86
Relative Strength Index (RSI)23.94
Average Volume (3m)1.34M
Important Dates
Immunotech Biopharm Ltd upcoming earnings date is Aug 21, 2026, TBA (Confirmed).
Last Earnings DateMar 20, 2026
Next Earnings DateAug 21, 2026
Ex-Dividend Date―
Financial Position
Immunotech Biopharm Ltd as a current ratio of 0.35, with Debt / Equity ratio of -3159.87%
Current Ratio0.35
Quick Ratio0.34
Debt to Market Cap0.23
Net Debt to EBITDA-3.34
Interest Coverage Ratio-23.50
Taxes
In the past 12 months, Immunotech Biopharm Ltd has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Immunotech Biopharm Ltd EV to EBITDA ratio is -15.85, with an EV/FCF ratio of -16.36.
EV to Sales0.00
EV to EBITDA-15.85
EV to Free Cash Flow-16.36
EV to Operating Cash Flow-18.82
Balance Sheet
Immunotech Biopharm Ltd has HK$154.63M in cash and marketable securities with HK$440.26M in debt, giving a net cash position of -HK$285.63M billion.
Cash & Marketable SecuritiesHK$154.63M
Total DebtHK$440.26M
Net Cash-HK$285.63M
Net Cash Per Share-HK$0.46
Tangible Book Value Per ShareHK$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunotech Biopharm Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-25.79%